in good shape lly important pharmacokinetic interactions with emtricitabine not expected 177 Etravirine No in vitro evidence of antagonistic antiretroviral effects 214 Famciclovir Pharmacokinetic interaction unlikely 1 Indinavir No effect on pharmacokinetics of either drug 1 Lamivudine In vitro evidence of additive antiretroviral effects 1 Do not use concomitantly with emtricitabine 1 200 201 (no potential benefit) Ledipasvir Fixed combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir): Clinically important pharmacokinetic interactions with emtricitabine not expected 181 Maraviroc No in vitro evidence of antagonistic antiretroviral effects 224 Nelfinavir In vitro evidence of additive to synergistic antiretroviral effects 1 Nevirapine In vitro evidence of additive or synergistic antiretroviral effects 1 Rilpivirine Pharmacokinetic interactions unlikely 226 No in vitro evidence of antagonistic antiretroviral effects 226 Ritonavir In vitro evidence of additive or synergistic antiretroviral effects 1 Saquinavir In vitro evidence of additive or synergistic antiretroviral effects 1 Simeprevir Clinically important interactions with emtricitabine not expected 187 Sofosbuvir No clinically important pharmacokinetic interactions with emtricitabine 188 Dosage adjustments not needed for either drug 188 Stavudine Pharmacokinetic interaction unlikely 1 In vitro evidence of additive or synergistic antiretroviral effects 1 Concomitant use with emtricitabine not recommended (increased toxicities) 200 201 Tenofovir No clinically important pharmacokinetic interactions 1 In vitro evidence of additive to synergistic antiretroviral effects 1 No in vitro evidence of antagonistic antiviral effects against HBV 1 Tipranavir In vitro evidence of additive antiretroviral effects 211 Zidovudine In vitro evidence of additive or synergistic antiretroviral effects 1 Emtricitabine Pharmacokinetics Absorption Bioavailability Pharmacokinetics in healthy individuals similar to those in individuals with HIV-1 infection. 1 Rapidly and extensively absorbed; peak plasma concentrations of emtricitabine attained within 1 2 hours. 1 Emtricitabine capsules: Bioavailability is 93%. 1 Emtricitabine oral solution: Bioavailability is 75%. 1 Fixed-combination tablet containing efavirenz 600 mg despite the fact that
Photo :lly important pharmacokinetic interactions with emtricitabine not expected 177 Etravirine No in vitro evidence of antagonistic antiretroviral effects 214 Famciclovir Pharmacokinetic interaction unlikely 1 Indinavir No effect on pharmacokinetics of either drug 1 Lamivudine In vitro evidence of additive antiretroviral effects 1 Do not use concomitantly with emtricitabine 1 200 201 (no potential benefit) Ledipasvir Fixed combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir): Clinically important pharmacokinetic interactions with emtricitabine not expected 181 Maraviroc No in vitro evidence of antagonistic antiretroviral effects 224 Nelfinavir In vitro evidence of additive to synergistic antiretroviral effects 1 Nevirapine In vitro evidence of additive or synergistic antiretroviral effects 1 Rilpivirine Pharmacokinetic interactions unlikely 226 No in vitro evidence of antagonistic antiretroviral effects 226 Ritonavir In vitro evidence of additive or synergistic antiretroviral effects 1 Saquinavir In vitro evidence of additive or synergistic antiretroviral effects 1 Simeprevir Clinically important interactions with emtricitabine not expected 187 Sofosbuvir No clinically important pharmacokinetic interactions with emtricitabine 188 Dosage adjustments not needed for either drug 188 Stavudine Pharmacokinetic interaction unlikely 1 In vitro evidence of additive or synergistic antiretroviral effects 1 Concomitant use with emtricitabine not recommended (increased toxicities) 200 201 Tenofovir No clinically important pharmacokinetic interactions 1 In vitro evidence of additive to synergistic antiretroviral effects 1 No in vitro evidence of antagonistic antiviral effects against HBV 1 Tipranavir In vitro evidence of additive antiretroviral effects 211 Zidovudine In vitro evidence of additive or synergistic antiretroviral effects 1 Emtricitabine Pharmacokinetics Absorption Bioavailability Pharmacokinetics in healthy individuals similar to those in individuals with HIV-1 infection. 1 Rapidly and extensively absorbed; peak plasma concentrations of emtricitabine attained within 1 2 hours. 1 Emtricitabine capsules: Bioavailability is 93%. 1 Emtricitabine oral solution: Bioavailability is 75%. 1 Fixed-combination tablet containing efavirenz 600 mg remedies emtricitabine 200 mg common
conceivable lly important pharmacokinetic interactions with emtricitabine not expected 177 Etravirine No in vitro evidence of antagonistic antiretroviral effects 214 Famciclovir Pharmacokinetic interaction unlikely 1 Indinavir No effect on pharmacokinetics of either drug 1 Lamivudine In vitro evidence of additive antiretroviral effects 1 Do not use concomitantly with emtricitabine 1 200 201 (no potential benefit) Ledipasvir Fixed combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir): Clinically important pharmacokinetic interactions with emtricitabine not expected 181 Maraviroc No in vitro evidence of antagonistic antiretroviral effects 224 Nelfinavir In vitro evidence of additive to synergistic antiretroviral effects 1 Nevirapine In vitro evidence of additive or synergistic antiretroviral effects 1 Rilpivirine Pharmacokinetic interactions unlikely 226 No in vitro evidence of antagonistic antiretroviral effects 226 Ritonavir In vitro evidence of additive or synergistic antiretroviral effects 1 Saquinavir In vitro evidence of additive or synergistic antiretroviral effects 1 Simeprevir Clinically important interactions with emtricitabine not expected 187 Sofosbuvir No clinically important pharmacokinetic interactions with emtricitabine 188 Dosage adjustments not needed for either drug 188 Stavudine Pharmacokinetic interaction unlikely 1 In vitro evidence of additive or synergistic antiretroviral effects 1 Concomitant use with emtricitabine not recommended (increased toxicities) 200 201 Tenofovir No clinically important pharmacokinetic interactions 1 In vitro evidence of additive to synergistic antiretroviral effects 1 No in vitro evidence of antagonistic antiviral effects against HBV 1 Tipranavir In vitro evidence of additive antiretroviral effects 211 Zidovudine In vitro evidence of additive or synergistic antiretroviral effects 1 Emtricitabine Pharmacokinetics Absorption Bioavailability Pharmacokinetics in healthy individuals similar to those in individuals with HIV-1 infection. 1 Rapidly and extensively absorbed; peak plasma concentrations of emtricitabine attained within 1 2 hours. 1 Emtricitabine capsules: Bioavailability is 93%. 1 Emtricitabine oral solution: Bioavailability is 75%. 1 Fixed-combination tablet containing efavirenz 600 mg hectic
EmoticonEmoticon